Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01433237 |
Recruitment Status
:
Completed
First Posted
: September 13, 2011
Last Update Posted
: May 19, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.
Condition or disease | Intervention/treatment |
---|---|
Sarcoma | Genetic: RNA analysis Genetic: gene expression analysis Other: laboratory biomarker analysis |
OBJECTIVES:
- Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).
OUTLINE: Archived serum samples are analyzed for miR-206 expression.
PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Observational Model: | Case Control |
Time Perspective: | Retrospective |
Official Title: | A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | May 2016 |
- Serum miR-206 as a biomarker for RMS

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
DISEASE CHARACTERISTICS:
- Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433237
Principal Investigator: | Hajime Hosoi, MD | Kyoto Prefectural University of Medicine |
Responsible Party: | Children's Oncology Group |
ClinicalTrials.gov Identifier: | NCT01433237 History of Changes |
Other Study ID Numbers: |
ARST12B1 COG-ARST12B1 ( Other Identifier: Children's Oncology Group ) ARST12B1 ( Other Identifier: Children's Oncology Group ) NCI-2011-03457 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) |
First Posted: | September 13, 2011 Key Record Dates |
Last Update Posted: | May 19, 2016 |
Last Verified: | May 2016 |
Keywords provided by Children's Oncology Group:
embryonal childhood rhabdomyosarcoma adult rhabdomyosarcoma alveolar childhood rhabdomyosarcoma adult soft tissue sarcoma childhood rhabdomyosarcoma |
Additional relevant MeSH terms:
Sarcoma Rhabdomyosarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type |
Neoplasms Myosarcoma Neoplasms, Muscle Tissue |